AstraZeneca PLC (AZN) Warns of Higher Costs as Drug Sales Slide  
8/1/2013 7:05:27 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

British drugmaker AstraZeneca warned on Thursday of higher costs in 2013 as it invests through a slump in sales caused by a wave of patent expiries on key medicines. The prediction that operating costs will now increase by a low-to-mid single digit percentage rate this year amounts to an effective cut in earnings guidance, analysts at Jefferies said. Deutsche Bank said consensus full-year earnings forecasts could fall by a couple of percent.

Help employers find you! Check out all the jobs and post your resume.